Nuray Aktay Ayaz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8901836/publications.pdf

Version: 2024-02-01

123 papers	1,518 citations	430843 18 h-index	395678 33 g-index
127 all docs	127 docs citations	127 times ranked	1853 citing authors

#	Article	IF	Citations
1	Performance of recent PRINTO criteria versus current ILAR criteria for systemic juvenile idiopathic arthritis: A single-centre experience. Modern Rheumatology, 2023, 33, 187-193.	1.8	4
2	Autoimmune and autoinflammatory diseases with mucocutaneous manifestations: A pediatric rheumatology perspective. International Journal of Dermatology, 2023, 62, 723-736.	1.0	1
3	Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatology International, 2022, 42, 879-889.	3.0	35
4	The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. Rheumatology International, 2022, 42, 469-475.	3.0	16
5	Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opinion on Biological Therapy, 2022, 22, 197-202.	3.1	5
6	Validity and reliability of four parent/patient reported outcome measures for juvenile idiopathic arthritis remote monitoring. Arthritis Care and Research, 2022, , .	3.4	2
7	Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey. Vaccine, 2022, 40, 1829-1836.	3.8	7
8	Editorial: Hereditary Periodic Fevers and Autoinflammatory Diseases. Frontiers in Pediatrics, 2022, 10, 855738.	1.9	1
9	What is the Role of Mucocutaneous Manifestations in the Clinical Presentation of Monogenic Autoinflammatory Diseases? A Singlecenter Experience. Bagcilar Medical Bulletin, 2022, 7, 70-76.	0.1	0
10	The Multifaceted Presentation of the Multisystem Inflammatory Syndrome in Children: Data from a Cluster Analysis. Journal of Clinical Medicine, 2022, 11, 1742.	2.4	6
11	Is There an Association Between Initial Clinical Manifestations and the Development of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis?. Medical Journal of Bakirkoy, 2022, 18, 31-36.	0.1	0
12	Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Rheumatology, 2022, 61, 4482-4490.	1.9	14
13	Is it all about age? Clinical characteristics of Kawasaki disease in the extremely young: PeRA research group experience. Postgraduate Medicine, 2022, 134, 429-434.	2.0	2
14	Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars. BioDrugs, 2022, , 1.	4.6	0
15	Cluster Analysis of Pediatric BehÃ§etâ€™s Disease: Data from The Pediatric Rheumatology Academy (PeRA)-Research Group (RG). Modern Rheumatology, 2022, , .	1.8	3
16	Comorbidities and phenotypeâ€“genotype correlation in children with familial Mediterranean fever. Rheumatology International, 2021, 41, 113-120.	3.0	30
17	Differential diagnosis portfolio of a pediatric rheumatologist: eight cases, eight stories. Clinical Rheumatology, 2021, 40, 769-774.	2.2	1
18	Comparison of the clinical diagnostic criteria and the results of the next-generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases. Clinical Rheumatology, 2021, 40, 2327-2337.	2.2	9

#	Article	IF	Citations
19	Systemic lupus erythematosus complicated with Castleman disease: a case-based review. Rheumatology International, 2021, 41, 475-479.	3.0	11
20	The relevance of practical laboratory markers in predicting gastrointestinal and renal involvement in children with Henochâ€“SchÃ¶nlein Purpura. Postgraduate Medicine, 2021, 133, 272-277.	2.0	16
21	Response to â€˜How to define disease severity accurately in patients with familial Mediterranean feverâ€™. Rheumatology International, 2021, 41, 239-240.	3.0	0
22	The influence of carrying MEFV gene variants on juvenile systemic lupus erythematosus. Rheumatology International, 2021, 41, 157-161.	3.0	4
23	The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods. Journal of Clinical Rheumatology, 2021, 27, 1-4.	0.9	9
24	The readiness of pediatric rheumatology patients and their parents to transition to adultâ€oriented treatment. International Journal of Rheumatic Diseases, 2021, 24, 397-401.	1.9	7
25	Evaluation of Children Referred to Pediatric Rheumatology Outpatient Clinic with Suspicious Laboratory Test Results. Ä°stanbul Kanuni Sultan SÃ¼leyman TÄ±p Dergisi, 2021, , .	0.0	0
26	Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey. Rheumatology International, 2021, , 1.	3.0	4
27	Neuroimaging of Children With Takayasu Arteritis. Journal of Child Neurology, 2021, 36, 642-647.	1.4	2
28	We might have the same mutation but my inflammasome beats your inflammasome: CINCA versus FCAS. ReumatologÃa ClÃnica, 2021, 17, 118-119.	0.5	0
29	Hepatitis B vaccination response of treatment-naive patients with juvenile idiopathic arthritis. Rheumatology International, 2021, , 1.	3.0	1
30	Comment on: Clinical significance of E148Q heterozygous variant in paediatric Familial Mediterranean Fever. Rheumatology, 2021, 60, e294-e295.	1.9	1
31	Approach to switching biologics in juvenile idiopathic arthritis: a real-life experience. Rheumatology International, 2021, , 1.	3.0	4
32	Sacroiliitis in children and adolescents with familial Mediterranean fever. Advances in Rheumatology, 2021, 61, 29.	1.7	4
33	Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study. Lupus, 2021, 30, 1983-1990.	1.6	9
34	Nailfold capillaroscopy: A sensitive method for evaluating microvascular involvement in children with SARS-CoV-2 infection. Microvascular Research, 2021, 138, 104196.	2.5	14
35	Age of onset as an influencing factor for disease severity in children with familial Mediterranean fever. Modern Rheumatology, 2021, 31, 219-222.	1.8	12
36	Comparison of Pediatric Familial Mediterranean Fever Patients Carrying Only E148Q Variant With the Ones Carrying Homozygous Pathogenic Mutations. Journal of Clinical Rheumatology, 2021, 27, 182-186.	0.9	7

#	Article	IF	Citations
37	Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus, 2021, 30, 2144-2150.	1.6	9
38	Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort. Frontiers in Pediatrics, 2021, 9, 805919.	1.9	22
39	The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 118-123.	0.8	0
40	The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients. Clinical and Experimental Rheumatology, 2021, 39, 118-123.	0.8	4
41	The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis. Modern Rheumatology, 2020, 30, 900-904.	1.8	12
42	Profile of new referrals to a single pediatric rheumatology center in Turkey. Rheumatology International, 2020, 40, 313-321.	3.0	9
43	Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections. Clinical Rheumatology, 2020, 39, 249-253.	2.2	6
44	Performance of Tel-Hashomer, Livneh, pediatric and new Eurofever/PRINTO classification criteria for familial Mediterranean fever in a referral center. Rheumatology International, 2020, 40, 21-27.	3.0	17
45	Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 yearsâ€™ experience of a tertiary pediatric rheumatology center. Rheumatology International, 2020, 40, 771-776.	3.0	5
46	ADA2 Deficiency: Case Series of Five Patients with Varying Phenotypes. Journal of Clinical Immunology, 2020, 40, 253-258.	3.8	17
47	Isotretinoinâ€induced sacroiliitis: Case series of four patients and a systematic review of the literature. Pediatric Dermatology, 2020, 37, 171-175.	0.9	5
48	Coexistence of Juvenile Systemic Lupus Erythematosus and Juvenile Spondyloarthropathy: A Case Report and Review of the Literature. Archives of Rheumatology, 2020, 35, 132-136.	0.9	0
49	Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19. Rheumatology International, 2020, 40, 1613-1623.	3.0	32
50	Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study. Rheumatology International, 2020, 40, 1111-1116.	3.0	8
51	Comorbidities of antiphospholipid syndrome and systemic lupus erythematosus in children. Current Rheumatology Reports, 2020, 22, 21.	4.7	4
52	Genetic panel screening in patients with clinically unclassified systemic autoinflammatory diseases. Clinical Rheumatology, 2020, 39, 3733-3745.	2.2	9
53	Rheumatic diseases in Syrian refugee children: a retrospective multicentric study in Turkey. Rheumatology International, 2020, 40, 583-589.	3.0	7
54	Characteristics of pediatric BehÃ§et's disease in Turkey and Israel: A cross-sectional cohort comparison. Seminars in Arthritis and Rheumatism, 2020, 50, 515-520.	3.4	18

#	Article	IF	Citations
55	The evaluation of anxiety, depression and quality of life scores of children and adolescents with familial Mediterranean fever. Rheumatology International, 2020, 40, 757-763.	3.0	18
56	Comment on â€˜Age dependent safety and efficacy of colchicine treatment for familial Mediterranean fever in childrenâ€™. Seminars in Arthritis and Rheumatism, 2020, 50, 1552.	3.4	0
57	Canakinumab in colchicine resistant familial mediterranean fever and other pediatric rheumatic diseases. Turkish Journal of Pediatrics, 2020, 62, 167.	0.6	10
58	How useful are Kawasaki disease risk scoring systems to the Turkish population?. Anatolian Journal of Cardiology, 2020, 24, 97-106.	0.9	10
59	Towards a combined pediatric rheumatology-dermatology clinic: One-year experience. Ä°stanbul Kuzey Klinikleri, 2020, 8, 37-41.	0.3	0
60	Immunodeficiency-Like Phenotype, Recurrent Pulmonary Manifestations, and Persistent Polyarthritis: Mevalonate Kinase Deficiency Successfully Treated With Adalimumab. Archives of Rheumatology, 2020, 35, 627-628.	0.9	1
61	Time to collaborate: Objectives, Design, and Methodology of PeRA-Research Group. Ä°stanbul Kuzey Klinikleri, 2020, 8, 200-202.	0.3	6
62	Like â€˜North Americansâ€™, â€˜Europeansâ€™, or â€˜Othersâ€™: Where do Turkish children with juvenile idiopathic arthritis stand in the new classification system?. Ä°stanbul Kuzey Klinikleri, 2020, 8, 421-422.	0.3	0
63	Anterior Segment Analysis and Evaluation of Corneal Biomechanical Properties in Children with Joint Hypermobility. TÃ¼rk Oftalmoloji Dergisi, 2020, 50, 71-74.	0.9	3
64	Otoinflamatuar Periyodik AteÅŸ SendromlarÄ±. The Journal of Child, 2020, 20, .	0.2	0
65	Leflunomide treatment in juvenile idiopathic arthritis. Rheumatology International, 2019, 39, 1615-1619.	3.0	16
66	Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2790-2800.e15.	3.8	112
67	Comment on: Short-term follow-up results of children with familial Mediterranean fever after cessation of colchicine: is it possible to quit?: reply. Rheumatology, 2019, 58, 1886-1887.	1.9	0
68	Short-term follow-up results of children with familial Mediterranean fever after cessation of colchicine: is it possible to quit?. Rheumatology, 2019, 58, 1818-1821.	1.9	12
69	Etiologic Spectrum and Follow-Up Results of Noninfectious Uveitis in Children: A Single Referral Center Experience. Archives of Rheumatology, 2019, 34, 294-300.	0.9	15
70	Why is the frequency of uveitis low in Turkish children with juvenile idiopathic arthritis?. Rheumatology, 2019, 59, 679-680.	1.9	2
71	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
72	The clinical spectrum of Henochâ€“SchÃ¶nlein purpura in children: a single-center study. Clinical Rheumatology, 2019, 38, 1707-1714.	2.2	30

#	Article	IF	Citations
73	Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. Rheumatology International, 2019, 39, 911-919.	3.0	37
74	THU0291â€...THE CHARACTERISTICS OF PEDIATRIC BEHÃ‡ETâ€™S DISEASE IN TURKEY VERSUS ISRAEL. , 2019, , .		0
75	SAT0522â€...COMPARISON OF CHILDREN CARRYING E148Q VARIANT WITH CHILDREN CARRYING HOMOZYGOUS PATHOGENIC VARIANTS. , 2019, , .		0
76	AB0991â€...PRELIMINARY RESULTS OF REFERRALS TO A TERTIARY PEDIATRIC RHEUMATOLOGY OUTPATIENT CLINIC: A YEAR IN REVIEW. , 2019, , .		0
77	AB0990â€...FINAL DIAGNOSIS OF THE PATIENTS WITH MUSCULOSKELETAL COMPLAINTS: PRELIMINARY RESULTS OF ONE-YEAR STUDY. , 2019, , .		0
78	AB1055â€...FINAL DIAGNOSES OF THE PATIENTS WHO WERE REFERRED TO A TERTIARY PEDIATRIC RHEUMATOLOGY OUTPATIENT CLINIC FOR LABORATORY ABNORMALITIES. , 2019, , .		0
79	AB0594â€...THE CLINICAL SPECTRUM OF HENOCH-SCHÃ–NLEIN PURPURA IN CHILDREN: A PROSPECTIVE SINGLE-CENTER STUDY. , 2019, , .		0
80	AB1061â€...SHORT TERM FOLLOW-UP RESULTS OF CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER AFTER CESSATION OF COLCHICINE: IS IT POSSIBLE TO QUIT?. , 2019, , .		0
81	FRI0536â€...FAMILIAL MEDITERRANEAN FEVER (FMF): A SINGLE CENTEREXPERIENCE FROM TURKEY. , 2019, , .		1
82	THU0524â€...ARE CHILDREN AND ADULTS HAVING DIFFERENT PHENOTYPE AND GENOTYPE OF FMF?. , 2019, , .		1
83	SAT0483â€...COMPARISON OF THE CLINICAL DIAGNOSTIC CRITERIA AND RESULTS OF THE NEXT GENERATION SEQUENCE GENE PANEL IN PATIENTS WITH PERIODIC FEVER. , 2019, , .		0
84	FRI0556â€...GENETIC SCREENING IN PATIENTS WITH UNDIFFERENTIATED PERIODIC FEVER SYNDROME. , 2019, , .		0
85	Corticosteroid-resistant anakinra-responsive protracted febrile myalgia syndrome as the first manifestation of familial Mediterranean fever. Ä°stanbul Kuzey Klinikleri, 2019, 7, 78-80.	0.3	5
86	Clinical experiences in turkish paediatric patients with chronic recurrent multifocal osteomyelitis. Turkish Journal of Pediatrics, 2019, 61, 879.	0.6	7
87	Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil. Turkish Journal of Pediatrics, 2019, 61, 771.	0.6	4
88	The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. Ä°stanbul Kuzey Klinikleri, 2019, 7, 118-123.	0.3	2
89	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 395-402.	3.0	4
90	Does familial Mediterranean fever affect cognitive function in children? Electrophysiological preliminary study. International Journal of Neuroscience, 2018, 128, 10-14.	1.6	4

#	Article	IF	Citations
91	Sustained hyperferritinemia in a child with macrophage activation syndrome secondary to systemic juvenile idiopathic arthritis - perforinopathy: case based review. Turkish Journal of Pediatrics, 2018, 60, 598.	0.6	2
92	A Case of Kawasaki Disease With Severe Lip and Oral Mucosa Involvement Complicated With Microstomia and Corrected With Surgery. Archives of Rheumatology, 2018, 33, 238-240.	0.9	5
93	An extreme entity in differential diagnosis of musculoskeletal involvement-fibrodysplasia ossificans progressiva: a case based review. Turkish Journal of Pediatrics, 2018, 60, 593.	0.6	0
94	Is there any difference regarding atopy between children with familial Mediterranean fever and healthy controls?. Allergologia Et Immunopathologia, 2017, 45, 549-552.	1.7	7
95	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	1.8	50
96	Subtype frequencies, demographic features, and remission rates in juvenile idiopathic arthritis - 265 cases from a Turkish center. Turkish Journal of Pediatrics, 2017, 59, 548-554.	0.6	18
97	Leptospirosis in a child with acute respiratory distress syndrome. Turkish Journal of Pediatrics, 2017, 59, 688.	0.6	0
98	Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever â€“ a randomized controlled noninferiority trial. Arthritis Research and Therapy, 2016, 18, 85.	3.5	18
99	Kawasaki disease shock syndrome: a rare and severe complication of Kawasaki disease. Turkish Journal of Pediatrics, 2016, 58, 415-418.	0.6	6
100	Coexistence of early onset sarcoidosis and partial interferon-Î³ receptor 1 deficiency. Turkish Journal of Pediatrics, 2016, 58, 545-549.	0.6	7
101	A case of chickenpox complicated with subacute osteomyelitis. Marmara Medical Journal, 2016, 29, 110.	0.8	1
102	Orbital muscle involvement in a child with familial Mediterranean fever. Marmara Medical Journal, 2016, 29, 124.	0.8	1
103	A novel assessment tool for clinical care of patients with autoinflammatory disease: juvenile autoinflammatory disease multidimensional assessment report. Clinical and Experimental Rheumatology, 2016, 34, 129-135.	0.8	22
104	Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging. Case Reports in Pediatrics, 2015, 2015, 1-4.	0.4	4
105	How Pricing And Reimbursement Policies Affect The Budget Impact of The Treatment of Systemic Juvenile Idiopathic Arthritis In Turkey. Value in Health, 2015, 18, A643.	0.3	0
106	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 994-1001.	2.0	59
107	How do we encounter rare factor deficiencies in children? Single-centre results from Turkey. Blood Coagulation and Fibrinolysis, 2015, 26, 145-151.	1.0	4
108	Cochlear functions in children with familial Mediterranean fever: Any role of the severity of the disease?. International Journal of Pediatric Otorhinolaryngology, 2015, 79, 1566-1570.	1.0	8

#	Article	IF	Citations
109	Granulocyte Transfusion in Febrile Neutropenia. Blood, 2015, 126, 4612-4612.	1.4	0
110	Dissecting the heterogeneity of macrophage activation syndrome. Pediatric Rheumatology, 2014, 12, .	2.1	0
111	Familial Mediterranean Fever: Diagnosing as Early as 3 Months of Age. Case Reports in Pediatrics, 2014, 2014, 1-3.	0.4	5
112	Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy. International Journal of Hematology, 2014, 99, 706-713.	1.6	6
113	Surgical interventions in childhood rare factor deficiencies. Blood Coagulation and Fibrinolysis, 2013, 24, 854-861.	1.0	4
114	Factor VII Deficiency. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 588-593.	1.7	19
115	Time to focus on outcome assessment tools for childhood vasculitis. Pediatric Rheumatology, 2011, 9, 29.	2.1	4
116	Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine: Table 1.. Journal of Rheumatology, 2011, 38, 516-518.	2.0	132
117	The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clinical and Experimental Rheumatology, 2011, 29, 111-6.	0.8	35
118	Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and BehÃ§etâ€™s disease. Clinical Rheumatology, 2010, 29, 209-210.	2.2	94
119	Preventing tuberculosis in children receiving anti-tnf treatment. Clinical Rheumatology, 2010, 29, 389-392.	2.2	20
120	BehÃ§et disease: treatment of vascular involvement in children. European Journal of Pediatrics, 2010, 169, 427-430.	2.7	33
121	Genotoxicity of antiâ€“tumor necrosis factor therapy in patients with juvenile idiopathic arthritis. Arthritis Care and Research, 2010, 62, 73-77.	3.4	12
122	Musculoskeletal sonography in juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 61, 58-60.	6.7	27
123	Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clinical Rheumatology, 2008, 27, 1317-1320.	2.2	55